{rfName}
Ph

Indexed in

License and use

Icono OpenAccess

Citations

3

Altmetrics

Impact on the Sustainable Development Goals (SDGs)

Analysis of institutional authors

Zubiaur P.Author

Share

Publications
>
Review

PharmVar GeneFocus: CYP4F2

Publicated to:CLINICAL PHARMACOLOGY & THERAPEUTICS. 116 (4): 963-975 - 2024-01-01 116(4), DOI: 10.1002/cpt.3405

Authors: Zubiaur P; Rodríguez-Antona C; Boone EC; Daly AK; Tsermpini EE; Khasawneh LQ; Sangkuhl K; Duconge J; Botton MR; Savieo J; Nofziger C; Whirl-Carrillo M; Klein TE; Gaedigk A

Affiliations

Abstract

The Pharmacogene Variation Consortium (PharmVar) serves as a global repository providing star (*) allele nomenclature for the polymorphic human CYP4F2 gene. CYP4F2 genetic variation impacts the metabolism of vitamin K, which is associated with warfarin dose requirements, and the metabolism of drugs, such as imatinib or fingolimod, and certain endogenous compounds including vitamin E and eicosanoids. This GeneFocus provides a comprehensive overview and summary of CYP4F2 genetic variation including the characterization of 14 novel star alleles, CYP4F2*4 through *17. A description of how haplotype information cataloged by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) is also provided.

Keywords

BiotecnologíaCiências biológicas iCiências biológicas iiFarmaciaGeneral medicineInterdisciplinarMedicina iMedicina iiMedicina iiiPharmacologyPharmacology & pharmacyPharmacology (medical)QuímicaSaúde coletiva

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal CLINICAL PHARMACOLOGY & THERAPEUTICS due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 25/354, thus managing to position itself as a Q1 (Primer Cuartil), in the category Pharmacology & Pharmacy. Notably, the journal is positioned above the 90th percentile.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-06-06:

  • Scopus: 3

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-06-06:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 1 (PlumX).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
Continuing with the social impact of the work, it is important to emphasize that, due to its content, it can be assigned to the area of interest of ODS 17 - Strengthen the means of implementation and revitalize the Global Partnership for Sustainable Development, with a probability of 41% according to the mBERT algorithm developed by Aurora University.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Austria; Brazil; Canada; Gran Bretanya; Puerto Rico; United Arab Emirates; United Kingdom; United States of America.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (ZUBIAUR PRECIOSO, PABLO) .